Gastrointestinal adenocarcinomas (GIACs) of the tubular GI tract including esophagus, stomach, colon and rectum comprise most GI cancers and share a spectrum of genomic features. However, the unified epigenomic changes specific to GIACs are less wellcharacterized.We applied mathematical algorithms to large-scale DNA methylome and transcriptome profiles to reconstruct transcription factor (TF) networks using 907 GIAC samples from The Cancer Genome Atlas (TCGA). Complementary epigenomic technologies were performed to investigate HNF4A activation, including Circularized Chromosome Conformation Capture (4C), Chromatin immunoprecipitation (ChIP) sequencing, Whole Genome Bisulfite Sequencing (WGBS), and Assay for Transposase-Accessible Chromatin (ATAC) sequencing. In vitro and in vivo cellular phenotypical assays were conducted to study HNF4A functions.
networks and particularly their enhancer regions and upstream regulators have not been well elucidated in a Pan-GIAC manner.
Genome-wide DNA methylation profiling has shown that enhancer de-methylation represents the most dynamic change that occurs during neoplastic development [13] [14] [15] [16] . Our earlier work demonstrated that this form of de-methylation could be used to identify cancerspecific enhancers which were strongly enriched for specific transcription factor binding sites (TFBSs) [14] . Recently, we have developed a novel computational algorithm, ELMER (Enhancer Linking by Methylation/Expression Relationships), to identify and exploit systematically these TFBS-associated methylation changes in cancer [17, 18] . Briefly, the approach of ELMER is to utilize TFBS methylation changes as key nodes within the larger gene regulatory network, and correlate with gene expression to infer both the upstream (master regulator TFs, MRTFs) and downstream (target genes) links for each TFBS. Specifically, when a group of enhancers is coordinately altered in a specific sample subset, this is often the result of an altered upstream MRTF in the gene regulatory network. To identify MRTFs involved in setting the tumor-specific DNA methylation patterns, ELMER correlates DNA methylation occurring within binding sites for specific MRTFs (inferred by specific TF binding motifs), with altered expression of the corresponding MRTF [17, 18] .
Considering the molecular similarities among GIACs, we hypothesized that there exist GIAC-specific gene regulatory networks which are controlled by GIAC-specific MRTFs. Here, we addressed this hypothesis by applying ELMER to TCGA Pan-GIAC samples to explore whether different GIACs share functionally hyperactive MRTFs.
Results

Identification of hyperactive MRTFs in GIAC using ELMER
To identify master regulator TFs (MRTFs) with higher transcriptional activity in GIACs than adjacent normal samples, we analyzed paired transcriptome sequencing (RNA-Seq) and DNA methylation array data (Infinium HM450 Beadchip) from TCGA samples, including EAC (78 tumors vs 5 normal), STAD (338 tumors vs 2 normal), and COAD (389 tumors vs 21 normal).
We additionally included PAAD (177 tumors vs 4 normal) since this cancer exhibits strong molecular similarity with a significant proportion of STAD, as introduced earlier[4]. The ELMER method was applied to compare tumor and normal specimens in each cancer type to identify MRTFs with higher activity in tumor samples ( Fig. 1A) . We further contrasted EAC vs ESCC tumors as they are biologically distinct subtypes from the same organ, serving as ideal analytical controls to discover EAC-specific networks. As a result, ELMER identified a total of 24 MRTFs (FDR q value <0.05), and notably, 10 of them were shared in at least two different comparisons (Fig. 1B) . This result suggests that different GIACs indeed exhibit notable similarity in terms of their hyperactive MRTFs, which likely control similar downstream transcriptional programs. Some of these MRTFs are well-established GIAC specific oncogenes, such as CDX2 [19, 20] , GATA6[10, 21] , KLF5 [10, 11] and HNF1A [22] , highlighting that ELMER is capable of identifying cancer-specific MRTFs.
Since this work was aimed to discover hyperactive MRTFs shared by different GIACs, we focused on the only three candidates (HNF4A, ELF3 and HNF1A) which were identified in at least three comparisons (Figs. 1B) . Among them, HNF4A was particularly interesting because: i) it had the lowest FDR q value among all 24 MRTFs; ii) it has been shown as an upstream regulator of HNF1A (another top-ranked MRTF) in hepatocytes [23] , which we functionally validated in different types of GIAC cells (Supplementary Fig. 1A) . Specifically, knockdown of HNF4A decreased the expression of HNF1A while the opposite was not observed (Supplementary Figs. 1B-C) . Moreover, HNF4A directly occupied the promoter region of HNF1A in several different GIAC cell lines (Supplementary Fig. 1A) . As shown in the scatter plots from each type of GIAC (Fig. 1C) , HNF4A-high tumors had significantly lower DNA methylation in predicted HNF4A binding regions than either HNF4A-low tumors or normal tissues. The ELMER analysis was based on the Infinium HM450 design, which covers less than Figs. 2A,B) . We next asked whether excessive levels of HNF4A could promote GIAC proliferation in GIAC cells with low endogenous HNF4A. Indeed, its ectopic over-expression enhanced the proliferation and colony formation in EAC, COAD and PAAD cells ( Figs. 4E-G) .
Considering that HNF4A is specifically activated in GIAC cancers, we next sought to test whether the functional significance of this MRTF exhibits similar GIAC specificity. Expectedly, HNF4A mRNA level was the highest in GIAC cells in a pan-cancer analysis of over 1,000 cell lines from CCLE (Cancer Cell Line Encyclopedia) [30] (Fig. 4H) . Strikingly, HNF4A was uniquely required for the viability of GIAC cells in the unbiased high-throughput shRNA screen ( Fig. 4H) . Consistent with our WGBS data, the HNF4A promoter was hypomethylated and correlated with high expression uniquely in GIAC cell lines in the CCLE dataset ( Fig. 4I) . We next tested whether its promoter methylation lever was similarly associated with its essentiality for cell viability. Indeed, cells with lower methylation of HNF4A promoter were more dependent on HNF4A for proliferation in a GIAC-specific manner (Fig. 4J) . These results together identified HNF4A as a prominent lineage-specific oncogene in GIAC tumors.
Targeting HNF4A suppresses growth of GIAC cancer cells and xenografts
Using a Dox-inducible shRNA system, we tested HNF4A function in vivo using an EACderived xenograft model (Fig. 5A) . Both the growth and weight of the tumor xenografts were significantly inhibited by HNF4A-silencing ( Figs. 5B-C) . IHC analysis showed that Ki-67 expression (a marker of cell proliferation) was down-regulated in HNF4A-knockdown tumors ( Fig. 5D) . We next investigated the function of HNF4A by a small-molecule inhibitor ) developed against this MRTF. This antagonist binds to HNF4A with high affinity by forming hydrogen bonds with HNF4A Arg226 and Gly237 which occupies a hydrophobic pocket.
This occupancy by BI-6015 inhibits the transcriptional function of HNF4A by preventing interaction with its ligand binding pocket. To test the effects of BI-6015 in vitro, we first conducted luciferase reporter assays using promoters from two direct HNF4A targets, HNF1A
and HNF4A itself (direct binding at the HNF1A promoter is shown in Supplementary Fig. 1A , and autoregulation of the HNF4A promoter is shown below). BI-6015 strongly inhibited the reporter activities of both promoters, as well as the mRNA levels of both genes (Fig. 5E) . In an in vitro proliferation assay, different GIAC cells from either EAC, PAAD or COAD were significantly more sensitive to this compound than non-GIAC cells (Figs. 5F-G), and that cell sensitivity to BI-6015 (measured by IC50) was negatively correlated with the expression of HNF4A ( Fig. 5H) , again confirming the on-target effect. The mouse xenograft assay showed that BI-6015 potently inhibited the growth of GIAC tumors but did not cause systematic toxicity ( Fig.   5I, Supplementary Figs. 3A,B) . Together, these results obtained from genetic and chemical approaches demonstrate that HNF4A functionally promotes the proliferation and survival specifically in GIAC cancer cells.
Upstream regulation of HNF4A transcription by GIAC MRTFs
To probe the mechanism underlying GIAC-unique epigenomic activation of HNF4A, we first performed circularized chromosome conformation capture (4C) sequencing to explore the interaction landscape of the HNF4A locus in EAC cells, using its promoter as the 4C-Seq bait (Viewpoint). We identified that all of the significant interactions (q < 0.001) were restricted to the 500kb window flanking the HNF4A promoter ( Fig. 6A) . Importantly, by cross-referencing H3K27Ac ChIP-Seq data generated in the matched sample, we found that the majority of interacting regions had positive H3K27Ac signals ( Fig. 6B ), suggesting their potential regulatory function. Based on the q value, we identified top 10 most significant interactions which overlapped with three H3K27Ac+ regions (referred to as E1-E3, Fig. 6C ). To search for potential TFs occupying these regions, we performed motif enrichment analysis and found that top enriched motifs included the GATA family, ELF3 and HNF4A itself (Fig. 6D) . This result was encouraging since GATA4/6 are known GIAC-specific MRTFs and ELF3 was the 2 nd most highly ranked MRTF identified earlier ( Fig. 1B) . Furthermore, the enrichment of HNF4A motif is also in keeping with the notion that self-regulation is an important and common property of many MRTFs in different cell types [32, 33] . To validate this motif analysis, we performed ChIP-Seq, wherein we additionally included KLF5 as our recent work identified it as an integral component of core regulatory circuitry (CRC) in EAC (Manuscript In Revision). Importantly, the ChIP-Seq results confirmed that the four regulatory regions (promoter region and E1-E3) were indeed occupied by GATA4, GATA6, ELF3, HNF4A and KLF5 in different types of GIAC cell lines ( Fig. 6C, Supplementary Fig. 4) . Notably, both E3 and promoter regions were cooccupied by all 5 MRTFs (Fig. 6C) . To test the transcriptional activity of these regulatory elements, they were cloned individually into the luciferase reporter vector. All three enhancer elements showed robust reporter activities uniquely in GIAC cells but not in SCC cells (Fig. 6E) .
Moreover, silencing each of the 5 MRTFs inhibited the activities of promoter and E3 region. In addition, ELF3, KLF5 and HNF4A contributed to the activity of E1 and E2 (Fig. 6F) . These results demonstrated strong and complex regulation of HNF4A transcription, which is GIACspecific and cooperatively controlled by GATA4, GATA6, ELF3, KLF5 and HNF4A itself. Importantly, individually silencing each MRTF significantly down-regulated the expression of HNF4A at both mRNA and protein levels, confirming the regulation of HNF4A by these factors (Fig. 7A-B) . Given the co-localization of these 5 MRTFs in HNF4A promoter and enhancers, we tested if there existed direct protein-protein interactions among these upstream factors. Immunoprecipitation (IP) analysis showed that GATA4, GATA6 and KLF5 formed protein complexes in GIAC cells ( Fig. 7C, Supplementary Fig. 5B ). While this protein complex did not contain HNF4A or ELF3, these two MRTFs might participate in the transcription cooperation through indirect mechanisms (indirect cooperativity, such as the "Billboard model" [34] ). Considering that some of these MRTFs (e.g., GATA4/6 and KLF5) have been reported to have copy number gains in GIAC samples [10, 11] , and our present work identified that HNF4A was also amplified specifically in GIACs, we next analyzed the genomic status of these MRTFs in TCGA dataset. The copy number gains of GATA4/6 and KLF5 were confirmed in both EAC and STAD cohorts ( Supplementary Fig. 5A) . Notably, the amplification of these MRTFs exhibited a mutually exclusive pattern ( Supplementary Fig. 5A ), strongly supporting our results that these MRTFs converge on HNF4A signaling, and thus redundant gain-of-function events are not required in the same GIAC samples.
HNF4A transcriptionally activates Interleukin signaling pathway in GIAC cells
To investigate the downstream targets of HNF4A in GIAC cells, we performed RNA-seq upon knockdown of this MRTF in ESO26 cells. Differential expression analysis of replicates identified 335 up-regulated genes and 346 down-regulated genes when compared with scrambled control (fold change > 2, p < 0.05). Pathway enrichment analysis of the differential expressed genes showed that a number of cancer-related pathways were top ranked, such as Interleukin signaling, WNT signaling and MAPK1/3 pathway ( Fig. 7D ). Among these, Interleukin signaling pathways were most notable, as they were the top 3 most significantly enriched. Specifically, a total of 21 genes of this pathway were downregulated upon knockdown of HNF4A. Integrating HNF4A ChIP-Seq results found that 14 of the 21 pathway components were directly bound by HNF4A ( Fig. 7E and Supplementary Table 2 ). We randomly selected a number of targets and RT-PCR analysis confirmed their expression changes ( Fig. 7F) . Some of these 14 direct targets (particularly ELK1, LYN, IL4R and IL6ST) have a pro-tumor properties in several cancer types [35] [36] [37] [38] [39] [40] [41] but their functions have not been explored in GIAC. We thus next tested whether they contributed to HNF4A-mediated oncogenic functions in GIAC cells. Importantly, silencing any of these 4 genes significantly inhibited the proliferation of GIAC cells ( Fig. 7G) . Together with our earlier result that HNF4A regulated HNF1A (another candidate GIAC MRTF, which also promoted GIAC cell proliferations, Supplementary Figs. 6A,B) , these data demonstrate that HNF4A plays an important role in promoting GIAC proliferation and survival by transcriptionally activating many downstream targets, including HNF1A and those belonging to the Interleukin signaling ( Fig. 8 ).
Discussion
The clinical management of GIACs has advanced only modestly over the last several decades, and thus urgent needs exist to decipher the biological and pathological basis of these malignancies to improve prevention, diagnosis and therapy. Recently, unbiased genomic studies have strongly suggested unified genomic features among different types of GIACs, which has prognostic and therapeutic implications. For example, MSI-high STAD and COAD patients have shown better clinical response to immune checkpoint blockade independent of anatomic tumor origin [5, 6] . In addition, ERBB2 amplified and overexpressed EAC, STAD and COAD patients similarly benefit from anti-Her2 therapy. Thus, identification and characterization of unified genomic and/or epigenomic features across different types of GIACs may have important clinical implications. In this study, we aimed to identify such shared epigenomic characteristics across anatomically distinct GIACs. Motivated by the prominent changes in DNA methylation and gene expression in cell type-and cancer-specificity manner, we inferred gene expression networks, cis-regulatory elements as well as their upstream MRTFs in different types of GIACs using a novel mathematical tool (ELMER) we developed previously. This algorithm provides an unbiased systematic approach to reconstruct gene regulatory networks by integrating matched methylome and gene expression data.
We found that different types of GIACs display notable similarity with respect to their hyperactive upstream MRTFs, which in turn conceivably orchestrate similar downstream transcriptional programs. Indeed, some of the MRTFs (such as GATA4/6, KLF5 and CDX2) are known to have similar oncogenic functions in different types of GIACs. As ELMER is based on DNA methylation array data which has limited resolution and representability, we generated WGBS results in an independent cohort of EAC and ESCC samples and successfully validated the ELMER prediction. These results highlight that our approach is capable of identifying bona fide MRTFs for cancer biology, and the list of candidate GIAC MRTFs warrant further investigation.
Focusing on the most significant MRTF, HNF4A, we first observed that the genomic and epigenomic activation of this factor was unique and specific in GIACs. Specifically, Pan-Cancer transcriptomic data from either TCGA or CCLE showed that the expression of HNF4A was uniquely high in GIACs comparing with other cancer types. Both internal IHC staining of different GIAC samples and Human Protein Atlas results consistently identified the same lineage-specific pattern of HNF4A protein. Moreover, higher HNF4A expression was associated with worse overall survival in different types of GIAC patients, supporting a shared functional contribution to GIAC biology independent of anatomic origin. Genomic analyses demonstrated that copy number amplification accounted partially for the GIAC-specific over-expression of HNF4A. The other important source to drive the high HNF4A level was epigenomic activation, which was supported by ATAC-Seq, WGBS as well as H3K27ac ChIP-Seq profiling. These epigenomic analyses identified that GIAC-specific open chromatin regions, which were concordantly de-methylated and had high H3K27ac signals, likely contributed to the transcriptional activation of HNF4A in GIAC in a lineage-specific manner. Prompted by this epigenomic observation, we next characterized the underlying mechanisms. We first applied 4C-Seq and identified three enhancer elements (E1-E3) interacting with the HNF4A promoter. Motif enrichment analysis of these regulatory regions coupled with ChIP-Seq experiments identified that they were occupied by five upstream GIAC-specific MRTFs, GATA4/6, ELF3, KLF5 and HNF4A itself. Luciferase reporter assays and loss-of-function experiments of individual MRTFs confirmed that HNF4A transcription is activated by these five MRTFs through interacting with HNF4A promoter and three local enhancers. HNF4A has been shown to be regulated by GATA4, GATA6 and KLF5 in STAD cells [10] , which is consistent with our unbiased motif search and epigenomic profiling. Furthermore, the self-regulatory property of HNF4A identified in the present study has been observed in many TFs in different cell types, which is regarded as an important and common characteristic of key MRTFs [32, 42] .
Functionally, HNF4A plays a role in normal development of the liver [43] [44] [45] , kidney [46] , and intestine [47, 48] . In cancer biology, HNF4A has opposite roles in different cell types. For example, HNF4A is a tumor suppressor in hepatocellular cancer [49] while it was required for maintaining the proliferation of STAD cells [10, 28, 29] . During the preparation of the manuscript, another study was published suggesting that HNF4A-mediated transcriptional program was more active in both Barrett's esophagus and EAC cells than normal esophageal squamous cells [50] . Using analysis from unbiased shRNA library screen of over 500 cancer cell lines, we showed that HNF4A is uniquely and specifically essential for the viability of GIAC cells. We further confirmed this finding using both genetic and chemical tools in different types of GIAC cells in vitro and in vivo, highlighting HNF4A as a prominent lineage-specific oncogene in GIAC tumors. Interestingly, a previous report showed that HNF4A activity could be inhibited by metformin [28] , making HNF4A an appealing and specific therapeutic target for GIAC, including early chemoprevention. We further performed ChIP-Seq and transcriptomic analysis and identified Interleukin signaling as a key downstream pathway of HNF4A.
Considering that agents inhibiting Interleukin signaling (such as Secukinumab, Ustekinumab and Ixekizumab) are available clinically, these results together highlight HNF4A-Interleukin axis as a potential actionable cascade for GIAC patients.
Conclusion
In summary, applying ELMER to matched DNA methylation and expression profiles to reconstruct TF networks, the present work identifies a panel of hyperactive MRTFs shared by different GIAC cancers. As a top candidate, HNF4A is highlighted as a key oncogenic MRTF with prominent genomic and epigenomic activations in GIAC-specific manner. By providing mechanistic insights into the upstream and downstream regulation of HNF4A, this work significantly advances our understanding of the GIAC-specific gene regulatory networks, while providing potential therapeutic strategies against these common cancers.
Methods
We applied mathematical algorithms to large-scale DNA methylome and transcriptome profiles to reconstruct transcription factor (TF) networks using 907 GIAC samples from The Cancer Genome Atlas (TCGA). Complementary epigenomic technologies were performed to investigate HNF4A activation, including Circularized Chromosome Conformation Capture (4C), Chromatin immunoprecipitation (ChIP) sequencing, Whole Genome Bisulfite Sequencing (WGBS), and Assay for Transposase-Accessible Chromatin (ATAC) sequencing. In vitro and in vivo cellular phenotypical assays were conducted to study HNF4A functions.
Antibodies and reagents
The following antibodies and reagents were used: Anti-HNF4A for ChIP-Seq and WB (Abcam, ab41898), Anti-HNF4A for IHC (a gift from Kenji Daigo and Takao Hamakubo), Anti-ELF3 (Santa Cruz Biotechnology, sc-376055 X), Anti-KLF5 (Santa Cruz Biotechnology, sc-398470 X), Anti-GATA6 (Cell Signaling Technology, 5851), Anti-GATA4 (Thermo Fisher Scientific, MA5-15532), Anti-HNF1A (Cell Signaling Technology,89670), Anti-FLAG (Sigma, F1804), Anti-Actin (Santa Cruz Biotechnology, sc-8432), Anti-H3K27Ac (Abcam, ab4729), Anti-mouse IgG-HRP (Jackson ImmunoResearch Laboratories, Inc., 115-035-003), Anti-rabbit IgG-HRP (Jackson ImmunoResearch Laboratories, Inc., 115-035-144), FITC Annexin V Apoptosis Detection Kit (BD Biosciences, 556547), Lipofectamine RNAiMAX (Thermo Fisher, 13778150)，BI-6015 (Cayman，12032) and siRNAs were purchased from Suzhou GenePharma Co., Ltd. (Sequences are provided in Supplementary Table 1 ).
Human cancer cell lines
Eso26, OACM5.1, SNU398 cells were grown in RPMI-1640 medium, and SKGT4, ASPC-1, Suit2, colo205 were cultured in Dulbecco's modified Eagle medium (DMEM). Eso26 and OACM5.1 were purchased from the American Type Culture Collection (ATCC). ASPC-1, Suit2, colo205 and SNU398 were purchased from JENNIO Biological Technology (Guangzhou, China).
Both media were supplemented with 10% fetal bovine serum (Omega Scientific, Tarzna, CA), 100 U/ml penicillin and 100 mg/ml streptomycin. All cell lines were verified by short tandem repeat analysis in the year of 2018.
ELMER analyses
Illumina HM450 methylation data from 4 different TCGA projects, COAD-READ, ESCA, PAAD, and STAD were processed with SeSAMe[51], and the matched RNA-seq (FPKM-UQ) data were downloaded from GDC (Genomic Data Commons, https://portal.gdc.cancer.gov/) from the harmonized database (data aligned to hg38/GRCh38). Unsupervised analysis was performed using ELMER[52] for the following pair-wise comparisons: EAC primary tumors (n = 78) vs ESCC primary tumors (n = 76); EAC primary tumors (n = 78) vs EAC normal adjacent samples (n = 5), COAD-READ primary tumors (n = 389) vs colon normal adjacent samples (n = 21), PAAD primary tumors (n = 177) vs pancreas normal adjacent samples (n = 4). Because of the small number of normal adjacent samples from STAD (n=2) which also lacked RNA-seq data, we could not perform comparison for STAD primary tumors. We applied the default probe filter "distal", which uses 160,944 probes that are > 2 kbp from any transcription start site as annotated by GENCODE 28. ELMER version 2.5.4 was used with the following parameters: WGBS reads were aligned to the genome (build GRCh38) using BISCUIT (https://github.com/zwdzwd/biscuit). Duplicated reads were marked using Picard Tools (https://broadinstitute.github.io/picard/). Methylation rates were called using BISCUIT. CpGs with fewer than 5 reads of coverage were excluded from further analysis. Quality control was performed using TrimGalore by default parameter for Illumina sequencing platforms, (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), PicardTools as well as MultiQC (https://multiqc.info/). Bisulfite non-conversion was checked using the Biscuit QC module in MultiQC (https://github.com/ewels/MultiQC/tree/master/multiqc/modules/biscuit).
ELMER-dependent motif analysis of WGBS
EAC and ESCC WGBS BED files were converted into Tag Directories using HOMER (http://homer.ucsd.edu/homer/) with the mCpGbed option. The annotatePeaks.pl script from HOMER was then run on all Tag Directories from each EAC and ESCC sample, with focal points defined as the list of predicted HNF4A motifs adjacent to EAC-demethylated CpGs, generated by ELMER (EAC vs. ESCC run described above). A bin size of 100bp for HOMER to generate spatial methylation plot.
ELMER-independent motif analysis of WGBS
The WGBS analysis was performed as described in the ELMER-dependent section above, except with different focal points. Here, we generated a set of predicted HNF4A binding sites by scanning the complete human genome using HOMER's scanMotifGenomeWide.pl at a p-value threshold of 1E-5. We used the same HOCOMOCO[54] HNF4A model as used in ELMER (http://hocomoco11.autosome.ru/motif/HNF4A_HUMAN.H11MO.0.A). We then filtered only those predicted HNF4A sites that overlapped one of the 72,264 esophageal-specific ATAC-seq peaks from TCGA [25] , aligning to the HNF4A motif for the spatial methylation plot. For the box plot, methylation was averaged within 20kb from each HNF4A motif.
CCLE data
We used dependency scores from the "Combined RNAi (Broad, Novartis, Marcotte)" field, expression values from the "Expression public 19Q2" field, and methylation values from the "Methylation (1kb upstream TSS)" field.
Chromatin immunoprecipitation (ChIP) sequencing
1x10 7~ 5x10 7 cells were harvested in 15 ml tubes and fixed with 2 ml of 1% paraformaldehyde for 10 min at room temperature, which was stopped by 2 ml of 250 mM of glycine. Samples were rinsed with 1xPBS twice and lysed twice with 1 ml of 1 X lysis/wash buffer (150 mM NaCl, 0.5 M EDTA pH 7.5, 1M Tris pH 7.5, 0.5% NP-40). Samples were filtered through a 29 G needle during each lysis process, and were harvested by centrifuge. Cell pellets were resuspended in sharing buffer (1% SDS, 10 mM EDTA pH 8.0, 50 nM Tris pH 8.0) and sonicated in a Covaris sonicator. The sonicated samples were subsequently centrifuged to remove debris and supernatants were diluted 5X with dilution buffer (0.01% SDS, 1% Triton X-100, 1.2 mM EDTA pH 8.0, 150 nM NaCl). The primary antibodies were then added and incubated by rotation at 4 overnight. Dynabeads Protein G beads (Life Technologies) were added the next morning and incubated by rotation for 4 hours. The beads were washed with 1x lysis/wash buffer followed by wash in cold TE buffer. DNA molecules were reverse crosslinked, purified and subject to library preparation and sequencing on Illumina HiSeq platform.
Immunohistochemistry (IHC) staining and quantification
Tissue microarrays were purchased from US Biomax Company (Col05-118e, ES8011a, PA804a). All slides were deparaffinized and immersed before incubating with anti-HNF4A antibody. IHC staining was performed at room temperature using a PowerVision Homo-Mouse IHC kit (ImmunoVision Technologies, Daly City, CA). Hematoxylin (Sigma) was used for counterstaining. HNF4A immunopositivity was scored as follows: 0, no staining or sporadic staining in < 5% cells; 1, weak staining in 5-25% cells; 2, weak staining in 26-50% of tumor cells; 3, strong staining in 26-50% cells; and 4, strong staining in > 50% cells.
Xenograft assays in nude mice
For shRNA-based experiments, 6 male six-week-old mice were randomly separated to two groups and subcutaneously injected with 2×106 Eso26 cells expressing inducible scrambled shRNA or shRNA against HNF4A. After tumor inoculation, all mice were fed with 2mg/ml doxycycline (Abcam, ab141091) containing water. For the BI-6015 experiment, 6 male sixweek-old mice were subcutaneously injected with 2×106 Eso26 cells. Either BI-6015 or vehicle control (5% DMSO+45% PEG 300+H2O) were administered three times per week by intraperitoneal injection at either 50 mg/kg or 100 mg/kg. Xenograft size was measured two times per week for a total of 4 weeks. Mice were euthanized at the end of experiment and xenograft tumors were extracted for analysis.
Construction of expression vectors
The pBABE-puro-HNF4A expression vector was amplified based on CMV-68 HNF4A (Addgene, #31092) and a 3xFLAG-tag was added via PCR. The amplified 3xFLAG-tagged HNF4A was then cloned into pBABE-puro vector (Addgene, #1764). The shRNA expression vector was designed based on siRNA sequences (provided in Supplementary Table 1 ) and cloned into Tet-pLKO-puro vector (Addgene, #21915) and pLKO-puro vector (Addgene, #8453). To produce viral particles, recombinant viral vectors and packaging vectors were co-transfected into 293T cells. Supernatants containing viral particles were harvested and filtered through a 0.45 µM filter 48 hours after transfection. GIAC cells were then infected with the virus in the presence of 10 mg/ml Polybrene.
In vitro cell proliferation assay
3,000 -5,000 GIAC cells were seeded into 96-well plates and cultured for indicated periods of time. For inhibitor treatment, culture medium was replaced with either DMSO-or BI-6015containing medium after 24 hours. Cell proliferation was measured by staining of 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
Luciferase reporter assay
Three enhancer elements (E1: chr20:42,838, 300-42,839,699, E2: chr20:42,931,956-42,930,286, E3: chr20: 43,035,000-43,037,051 and negative control chr20:42,860,825-42,862,318) were cloned into pGL3-Promoter luciferase reporter vector (Promega). HNF4A promoter luciferase reporter vector HNF4A-P2-2200 was purchased from Addgene (Addgene, 31062). HNF1A promoter luciferase reporter vector HNF1A-P-1526 was cloned in house. A Renilla luciferase control vector was co-transfected for normalization. After 48 hours of transfection, the reporter activity was measured by the Dual-Luciferase Reporter Assay System (Promega, E1910).
Preparation of 4C-Seq library
4C-Seq libraries were prepared using our previous described protocols [55] . In brief, Eso26 cells were single-cell suspended, and the chromatin was cross-linked with 1% formaldehyde at room temperature. Cells were lysed and DNA was digested with the restriction enzyme TaqI (R0149L, NEB). Digested DNA was next ligated using T4 DNA ligase (EL0013, Thermo Scientific), followed by removal of cross-link using Proteinase K (19133, Qiagen), yielding 3C libraries. These 3C libraries were subjected to a second enzyme digestion by Csp6i (R0639L, NEB), followed by another ligation using T4 DNA ligase. A total of 3.2 µg of the resulting 4C templates was used for a scale-up inverse nested PCR for 29 cycles. The PCR products were purified using Macherey Nagel Nucleospin Gel and PCR Purification kit (Takara Bio). 4C sequencing libraries were made from the PCR products using Thruplex DNA-seq kit (R400427, Takara Bio). The libraries were subjected to Agencourt AMPure XP Bead clean-up (A63881, Beckman Coulter) using a bead-to-DNA ratio of 1:1. Libraries were sequenced using 1 X 75bp for 2 million read depth using MiniSeq system (Illumina).
Primer design for 4C-Seq
The inverse primers were designed based on a viewpoint region. DpnII restriction sites flanking the region of interest were identified and the sequence between the nearest DpnII and TaqI restriction sites were selected as the viewpoint region. Based on this region, 4C primers (F1-AGGAGACGGACCTTAATCAGATC, R1-AATGTGACCGCTTCCCTAAGCT) were designed with the following settings: optimal melting temperature of 60 C (57 C -62 C); GC content: 40 -60%.
4C-Seq data analysis
4C sequencing data were analyzed using the R package r3CSeq [56] . Briefly, for each replicate the raw reads were aligned to the reference human genome which was masked for the gap, repetitive and ambiguous sequences. The masked version of the genome was downloaded from the R Bioconductor repository (BSgenome.Hsapiens.UCSC.hg19.masked). The number of mapped reads for each window were counted and normalized to obtain RPM (reads per million per window) values, which was used to perform statistical analysis. Interacted regions were plotted and visualized on UCSC Genome Browser as custom tracks. 4C sequencing data have been deposited to Gene Expression Omnibus (GSE132813, token: ehixwcucnjoxvsb).
ChIP-Seq data analysis
We generated ChIP-Seq data for HNF4A and GATA4 in Eso26 cells in the present work, which has been deposited to Gene Expression Omnibus (GSE132813, token: ehixwcucnjoxvsb).
ChIP-Seq data of GATA6, KLF5 and ELF3 in Eso26 cells, and H3K27Ac ChIP-Seq data in the following cell lines were generated in-house recently (GSE132686 and GSE106563) [57, 58] : 
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Figure 4. HNF4A specifically promotes the proliferation and survival of GIAC cells
In EAC (Eso26), COAD (Colo205) and PAAD (Suit2) cell lines, HNF4A expression was silenced by three different shRNAs and followed by Western Blotting assay (A), cell proliferation assay (B), colony formation assay (C), and apoptosis assays (D). In (E), HNF4A was ectopically expressed and validated by Western Blotting in EAC (SKGT4 and OACM5.1), COAD (SNU398) and PAAD (ASPC-1) cells.
HNF4A-overexpressing cells were subjected to cell proliferation (F) and colony formation ( 
